Curriculum vitae Professor Dr. med. Christoph Thomssen

Curriculum vitae Professor Dr. med. Christoph Thomssen Universitätsklinik und Poliklinik für Gynäkologie Universitätsklinikum Halle-Kröllwitz

Ernst-Grube-Strasse 40 D-06097 Halle (Saale) Germany Tel.: +49-345-557-1847 Fax: +49-345-557-1501 e-mail: [email protected]

Curriculum Vitae Professor Dr. med. Christoph Thomssen

2

Curriculum Vitae Professor Dr. med. Christoph Thomssen

Name

Christoph Thomssen, born January 5, 1957 in Waldshut/Hochrhein

University education 1976 - 1978 1978 - 1983 1982 - 1983 1983 1989 1998 2001 2004

Medical School at the Georg-August-Universität Göttingen (preclinical part) Medical School at the Technische Universität München (clinical part) Medical internship Graduation in medicine (M.D., „Approbation“) M.D. thesis (“Dr. med.”). Thesis advisor: Prof. Dr. med. H. J. Möller, Department of Psychiatry, Technische Universität Munich) Lecturer’s thesis (“Privatdozent”) at the Faculty of Medicine of the University Hamburg University-Professor for Obstetrics and Gynaecology at the University Hamburg University-Professor for Obstetrics and Gynaecology at the Martin-LutherUniversity Halle-Wittenberg (Ordinarius))

Professional appointments 1984 - 1986 1986 - 1996 1991 1992 1996 2003 2004

Residency at the Department of Obstetrics and Gynaecology of the District Hospital Fürstenfeldbruck (Director: Dr. med. Sixtus Keck) Residency and Fellowship at the Department of Obstetrics and Gynaecology of the Technische Universität München (Director: Prof. Dr. med. Henner Graeff) Specialist's degree in Obstetrics and Gynaecology (German National Board Examination) Senior physician at the Department of Obstetrics and Gynaecology of the Technische Universität Munich Senior physician and assistant director at the Department of Obstetrics and Gynaecology, University of Hamburg (Director: Prof. Dr. med. Fritz Jänicke) Director (comm.) of the Department of Gynecology at the University Halle / S Director of the Department of Gynaecology at the University Halle / S

Subjects of Research Clinical Oncology: Breast cancer: treatment of primary disease and recurrence; adjuvant and palliative therapy, prognostic and predictive factors; endocrine therapy, chemotherapy incl. dose-intense chemotherapy; axillary dissection, quality of life. Ovarian Cancer: secondary surgery. Cervical Cancer: neoadjuvant chemotherapy, surgery. Clinical Studies: Participation in study design and coordination of 12 clinical studies; participation total in more than 35 studies. Obstetrics: Prenatal diagnosis, Doppler sonography. Memberships: American Association of Cancer Research (AACR), Deutsche Krebsgesellschaft (DKG), Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Arbeitsgruppe Gynäkologische Onkologie (AGO), EORTC Biomarker and Receptor Study Group (RBSG), EORTC Breast Cancer Cooperative Group (BCCG), Tumorzentrum Munich (Projektgruppen:

Curriculum Vitae Professor Dr. med. Christoph Thomssen

3

„Endometriumkarzinom/ Zervixkarzinom“, „Mammakarzinom“, „Ovarialkarzinom“), Tumorzentrum Hamburg (AKOG), Nordostdeutsche Gesellschaft für Geburtshilfe und Gynäkologische Onkologie (NOGGO), Medizinisch-Wissenschaftliche Gesellschaft für Gynäkologie und Geburtshilfe in Sachsen-Anhalt e. V.

Publications >80 original papers and review papers 32 book articles und published lectures > 200 abstracts and letters > 500 lectures and oral presentations

Clinical studies (listed only if participation in study design or coordination) (*multicenter studies) 1. *Mitoxantrone single agent treatment in metastatic breast cancer 2. *Triple-M as neoadjuvant therapy of locally advanced breast cancer 3. Oxytocin IV vs. oxytocin as intranasal spray in contraction stress test 4. *Adjuvant chemotherapy in node-negative breast cancer guided risk adapted selection by tumorbiologic prognostic factors: uPA und PAI-1 (multicentric trial supported by DFG). 5. *High dose-intensity chemotherapy in high-rik breast cancer (N1biii or >10 ax. Lnn.): diEC vs. EC/CMF. 6. Taxol in first line-treatment of metastatic breast cancer. 7. Fibronectin in cervical mucus as predictor of response to labour inducing measures (randomised trial). 8. *Epirubicin and paclitaxel in first line-chemotherapy in metastatic breast cancer: Phase IIstudy. 9. *Epirubicin and paclitaxel in comparison to epirubicin and cyclophosphamide in first-line therapy of patients with metastatic breast cancer. 10. *Adjuvant chemotherapy (ETC) in a dose-intense approach with shortened intervals versus sequential standard chemotherapy (ECT) in high-risk patients with nodepositive breast cancer (4 - 9 ax. Lnn.). A Phase-II study. 11. *Sequential chemotherapy (ETC)  Epoetin- in a dose-intense approach with shortened intervals versus sequential standard chemotherapy (ECT) in high-risk patients with node-positive breast cancer (4 - 9 ax. Lnn.). Open randomised, prospective, multicentric phase III-therapy optimization. 12. *Randomised comparison of a neoadjuvant, dose-intense sequential chemotherapy with epirubicin and paclitaxel versus a neoadjuvant chemotherapy with epirubicin and paclitaxel in standard dose in patients with primary breast cancer. 13. *Adjuvant chemotherapy in node-negative breast cancer patients guided by prognostic (uPA/PAI-1) and predictive (c-erbB-2) factors. A multicentric, prospective and randomized trial on the predictive value of c-erbB-2 overexpression in adjuvant chemotherapy of high-risk node-negative breast cancer patients defined by

Curriculum Vitae Professor Dr. med. Christoph Thomssen

4

tumorbiological factors (uPA/PAI-1). (Europäische Multicenterstudie, Studienleitung). (LKP) 14. *Cardiac safety of recombinant humanized anti-p185HER-2/neu monoclonal antibody trastuzumab in combination with epirubicin/cyclophosphamide as first line therapy in anthracycline-naïve patients with HER-2/neu overexpressing metastatic breast cancer 15. *Phase II-trial Taxol/5-FU in patients with metastatic breast cancer recurrent after highdose chemotherapy with stem cell support. 16. *Phase I/II-trial on concurrent radio-chemotherapy in inoperable cervical cancer. 17. *HERA – Herceptin adjuvant in HER-2 overexpressin breast cancer (Member of the international steering committee). 18. *GAIN - Phase III- trial to compare ETC vs. EC-TX and Ibandronat vs. observation in patients with node-positiv primary breast cancer 19. *ATHENA - Open-label study of bevacizumab (AVASTIN®) plus taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer (LKP) 20. *ALTTO – Adjuvant Lapatinib and/or Trastuzumab treatment optimisation study